Alitretinoin Compliance in Patients with Chronic Hand Eczema
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Oral alitretinoin is effective in the treatment of chronic hand eczema (CHE), and ≥12 weeks of alitretinoin treatment has been shown to be effective in Korean patients. However, in the real world, a considerable number of patients discontinue alitretinoin, which leads to treatment failure. Objective: To evaluate the compliance rate of alitretinoin treatment and explore common reasons for poor compliance in patients with CHE in the real world. Methods: We retrospectively reviewed the electronic medical records of CHE patients treated with alitretinoin. We defined ‘poor-compliance’ as subjects who were treated with alitretinoin for ＜12 weeks and ‘good-compliance’ as subjects who were treated with alitretinoin for ≥12 weeks. We reviewed the demographics, dose, and duration of alitretinoin usage, efficacy, and reasons for poor compliance. Results: A total of 137 subjects were enrolled, and 77 (56.2%) did not complete the 12-week treatment with alitretinoin. Among them, the non-improvement rate was significantly higher in the poor-compliance group than in the good-compliance group (p＜0.01). The main reasons for the alitretinoin cessation in the poor-compliance group were insufficient response (40.8%), followed by high cost (34.7%), and adverse events (24.5%). Conclusion: Alitretinoin appears the preferred longterm treatment option for CHE. Although there are complaints about late efficacy, cost, and side effects, following proper explanation, these should not justify discontinuation. Physicians need to recognize the reasons for poor compliance with alitretinoin for each patient and suggest continuing alitretinoin for the successful treatment of CHE
Abstract
Background: Oral alitretinoin is effective in the treatment of chronic hand eczema (CHE), and ≥12 weeks of alitretinoin treatment has been shown to be effective in Korean patients. However, in the real world, a considerable number of patients discontinue alitretinoin, which leads to treatment failure. Objective: To evaluate the compliance rate of alitretinoin treatment and explore common reasons for poor compliance in patients with CHE in the real world. Methods: We retrospectively reviewed the electronic medical records of CHE patients treated with alitretinoin. We defined ‘poor-compliance’ as subjects who were treated with alitretinoin for ＜12 weeks and ‘good-compliance’ as subjects who were treated with alitretinoin for ≥12 weeks. We reviewed the demographics, dose, and duration of alitretinoin usage, efficacy, and reasons for poor compliance. Results: A total of 137 subjects were enrolled, and 77 (56.2%) did not complete the 12-week treatment with alitretinoin. Among them, the non-improvement rate was significantly higher in the poor-compliance group than in the good-compliance group (p＜0.01). The main reasons for the alitretinoin cessation in the poor-compliance group were insufficient response (40.8%), followed by high cost (34.7%), and adverse events (24.5%). Conclusion: Alitretinoin appears the preferred longterm treatment option for CHE. Although there are complaints about late efficacy, cost, and side effects, following proper explanation, these should not justify discontinuation. Physicians need to recognize the reasons for poor compliance with alitretinoin for each patient and suggest continuing alitretinoin for the successful treatment of CHE
참고문헌 (15)
- 권형일, "Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients", Annals of Dermatology, 28(3), pp.364~370 (2016), 대한피부과학회
- Blank PR, "Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective", BMC Dermatol, 10, pp.4~ (2010)
- Politiek K, "Alitretinoin and acitretin in severe chronic hand eczema;results from a retrospective daily practice study", Dermatol Ther, 29, pp.364~371 (2016)
- Morris M, "Safety of alitretinoin for severe refractory chronic hand eczema : clinical studies and postmarketing surveillance", J Dermatolog Treat, 27, pp.54~58 (2016)
- Diepgen TL, "Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions : results of the TOCCATA open study comprising 680 patients", Acta Derm Venereol, 92, pp.251~255 (2012)
- Ruzicka T, "Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial", Br J Dermatol, 158, pp.808~817 (2008)
- 최명순, "손 습진 환자의 임상적 고찰", 대한피부과학회지, 47(12), pp.1331~1337 (2009), 대한피부과학회
- English JS, "Recent advances in the management of hand dermatitis : does alitretinoin work", Clin Dermatol, 29, pp.273~277 (2011)
- Kazemi T, "Isotretinoin therapy : a retrospective cohort analysis of completion rates and factors associated with nonadherence", J Am Acad Dermatol, 79, pp.571~573 (2018)
- Al-Dhubaibi MS, "The effectiveness of alitretinoin for the treatment of chronic hand eczema: a meta-analysis", Int J Health Sci(Qassim), 12, pp.70~79 (2018)
- Fowler JF, "A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy", J Drugs Dermatol, 13, pp.1198~1204 (2014)
- Ghasri P, "Update on the use of alitretinoin in treating chronic hand eczema", Clin Cosmet Investig Dermatol, 3, pp.59~65 (2010)
- 강준만, "‘빨리빨리’의 문화정치학: 한국의 ‘속도 커뮤니케이션’에 관한 연구", 언론과학연구, 10(3), pp.47~80 (2010), 한국지역언론학회
- Gulliver WP, "Effective treatment of chronic hand dermatitis with 36 continuous months of alitretinoin administration : report of three cases", J Cutan Med Surg, 16, pp.267~271 (2012)
- Schmitt-Hoffmann AH, "Pharmacokinetics, efficacy and safety of alitretinoin in moderate or severe chronic hand eczema", Clin Exp Dermatol, 36(Suppl 2), pp.29~34 (2011)